Phuong D, Pirtz M, Ralston C, Cosgrove B, Schimenti J, Flesken-Nikitin A
Cancers (Basel). 2025; 17(4).
PMID: 40002199
PMC: 11852459.
DOI: 10.3390/cancers17040604.
Paradowska E, Hareza D, Kania K, Jarych D, Wilczynski M, Malinowski A
Sci Rep. 2024; 14(1):21602.
PMID: 39284893
PMC: 11405690.
DOI: 10.1038/s41598-024-72814-0.
Chen S, Huang L, Liang M, Xie Y, Zhou Z, Ke Y
Front Mol Biosci. 2024; 11:1429852.
PMID: 39281319
PMC: 11392903.
DOI: 10.3389/fmolb.2024.1429852.
Wang Z, Liang X, Yi G, Wu T, Sun Y, Zhang Z
Cancer Rep (Hoboken). 2024; 7(2):e1933.
PMID: 38321787
PMC: 10864729.
DOI: 10.1002/cnr2.1933.
Mujawar A, Phadte P, Palkina K, Markina N, Mohammad A, Thakur B
Sensors (Basel). 2023; 23(17).
PMID: 37687774
PMC: 10490530.
DOI: 10.3390/s23177313.
Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers.
Atallah G, Kampan N, Chew K, Mokhtar N, Md Zin R, Shafiee M
Int J Mol Sci. 2023; 24(3).
PMID: 36768291
PMC: 9916805.
DOI: 10.3390/ijms24031973.
The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.
Wallis B, Bowman K, Lu P, Lim C
Biomolecules. 2023; 13(1).
PMID: 36671544
PMC: 9855757.
DOI: 10.3390/biom13010159.
Ovarian Microbiota, Ovarian Cancer and the Underestimated Role of HPV.
Cazzaniga M, Cardinali M, DI Pierro F, Bertuccioli A
Int J Mol Sci. 2022; 23(24).
PMID: 36555661
PMC: 9784802.
DOI: 10.3390/ijms232416019.
The regulatory landscape of retinoblastoma: a pathway analysis perspective.
Gomez-Romero L, Alvarez-Suarez D, Hernandez-Lemus E, Ponce-Castaneda M, Tovar H
R Soc Open Sci. 2022; 9(5):220031.
PMID: 35620002
PMC: 9114937.
DOI: 10.1098/rsos.220031.
The senescence-associated secretory phenotype in ovarian cancer dissemination.
Veenstra J, Bittencourt L, Aird K
Am J Physiol Cell Physiol. 2022; 323(1):C125-C132.
PMID: 35584328
PMC: 9273281.
DOI: 10.1152/ajpcell.00049.2022.
Folate Transport and One-Carbon Metabolism in Targeted Therapies of Epithelial Ovarian Cancer.
Wallace-Povirk A, Hou Z, Nayeen M, Gangjee A, Matherly L
Cancers (Basel). 2022; 14(1).
PMID: 35008360
PMC: 8750473.
DOI: 10.3390/cancers14010191.
MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer.
Mirahmadi Y, Nabavi R, Taheri F, Samadian M, Ghale-Noie Z, Farjami M
J Oncol. 2021; 2021:3408937.
PMID: 34721577
PMC: 8553480.
DOI: 10.1155/2021/3408937.
The hallmarks of ovarian cancer: proliferation and cell growth.
Lopez-Reig R, Lopez-Guerrero J
EJC Suppl. 2020; 15:27-37.
PMID: 33240440
PMC: 7573473.
DOI: 10.1016/j.ejcsup.2019.12.001.
Prognostic Significance of Prostaglandin-Endoperoxide Synthase-2 Expressions in Human Breast Carcinoma: A Multiomic Approach.
Saindane M, Rallabandi H, Park K, Heil A, Nam S, Yoo Y
Cancer Inform. 2020; 19:1176935120969696.
PMID: 33223820
PMC: 7656875.
DOI: 10.1177/1176935120969696.
Novel protein and immune response markers of human serous tubal intraepithelial carcinoma of the ovary.
Gutkin D, Shurin M, El Azher M, Shurin G, Velikokhatnaya L, Prosser D
Cancer Biomark. 2019; 26(4):471-479.
PMID: 31658047
PMC: 6928436.
DOI: 10.3233/CBM-190528.
Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.
Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E
Oncogene. 2018; 37(43):5701-5718.
PMID: 29915391
PMC: 6202330.
DOI: 10.1038/s41388-018-0368-z.
A computational framework for complex disease stratification from multiple large-scale datasets.
De Meulder B, Lefaudeux D, Bansal A, Mazein A, Chaiboonchoe A, Ahmed H
BMC Syst Biol. 2018; 12(1):60.
PMID: 29843806
PMC: 5975674.
DOI: 10.1186/s12918-018-0556-z.
CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer.
Iyengar M, OHayer P, Cole A, Sebastian T, Yang K, Coffman L
Oncotarget. 2018; 9(21):15658-15672.
PMID: 29644000
PMC: 5884655.
DOI: 10.18632/oncotarget.24585.
Molecularly targeted therapies for p53-mutant cancers.
Zhao D, Tahaney W, Mazumdar A, Savage M, Brown P
Cell Mol Life Sci. 2017; 74(22):4171-4187.
PMID: 28643165
PMC: 5664959.
DOI: 10.1007/s00018-017-2575-0.
Plakoglobin Reduces the in vitro Growth, Migration and Invasion of Ovarian Cancer Cells Expressing N-Cadherin and Mutant p53.
Alaee M, Danesh G, Pasdar M
PLoS One. 2016; 11(5):e0154323.
PMID: 27144941
PMC: 4856367.
DOI: 10.1371/journal.pone.0154323.